Simulect : EPAR - All Authorised presentations
Submitted by Anonymous (not verified) on 12 October 2023 - 10:49
Simulect : EPAR - All Authorised presentations
Day 80 assessment report - Non-clinical template with guidance - Rev.10.23 Revamp
Submitted by Anonymous (not verified) on 12 October 2023 - 10:40
Day 80 assessment report - Non-clinical template with guidance - Rev.10.23 Revamp
Day 80 assessment report - Clinical template with guidance - Rev.10.23 Revamp
Submitted by Anonymous (not verified) on 12 October 2023 - 10:34
Day 80 assessment report - Clinical template with guidance - Rev.10.23 Revamp
Human medicines European public assessment report (EPAR): Cometriq, cabozantinib, Thyroid Neoplasms, Date of authorisation: 21/03/2014, Revision: 28, Status: Authorised
Submitted by Anonymous (not verified) on 12 October 2023 - 10:29
Human medicines European public assessment report (EPAR): Cometriq, cabozantinib, Thyroid Neoplasms, Date of authorisation: 21/03/2014, Revision: 28, Status: Authorised
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 5-7 September 2023
Submitted by Anonymous (not verified) on 12 October 2023 - 8:56
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 5-7 September 2023
European Medicines Agency post-authorisation procedural advice for users of the centralised procedure
Submitted by Anonymous (not verified) on 11 October 2023 - 17:10
European Medicines Agency post-authorisation procedural advice for users of the centralised procedure
Notifying a change of marketing status
Submitted by Anonymous (not verified) on 11 October 2023 - 17:00
Notifying a change of marketing status
Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Lymphoma, Large B-Cell, Diffuse;Lymphoma, Follicular;Mediastinal Neoplasms, Date of authorisation: 04/04/2022, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 11 October 2023 - 15:45
Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Lymphoma, Large B-Cell, Diffuse;Lymphoma, Follicular;Mediastinal Neoplasms, Date of authorisation: 04/04/2022, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Alofisel, darvadstrocel, Rectal Fistula, Date of authorisation: 23/03/2018, Revision: 11, Status: Authorised
Submitted by Anonymous (not verified) on 11 October 2023 - 11:07
Human medicines European public assessment report (EPAR): Alofisel, darvadstrocel, Rectal Fistula, Date of authorisation: 23/03/2018, Revision: 11, Status: Authorised
Human medicines European public assessment report (EPAR): Rukobia, fostemsavir, HIV Infections, Date of authorisation: 04/02/2021, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 11 October 2023 - 7:28
Human medicines European public assessment report (EPAR): Rukobia, fostemsavir, HIV Infections, Date of authorisation: 04/02/2021, Revision: 4, Status: Authorised